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Abstract
Background: Dysregulation of microRNAs (miRNAs) is actively involved in the pathogenesis and tumorigenicity of
colorectal cancer (CRC). miR-296 was found to play either oncogenic or tumor suppressive role in human cancers.
However, the status of miR-296 and its function in CRC remain unknown.
Methods: The expression of miR-296 was confirmed by qRT-PCR in CRC tissues and cells, and its level was altered
by corresponding miRNA vectors. Wound healing and Transwall assays were performed to detect the migration
and invasion of CRC cells. The levels of proteins were measured using immunoblotting, immunohistochemistry and
immunofluorescence.
Results: Underexpression of miR-296 was disclosed in CRC tissues and cells. Its decreased level was evidently correlated
with adverse clinical parameters and poor prognosis of CRC patients. In vitro experiments indicated that miR-296
inhibited CRC cell migration and invasion. Mechanically, miR-296 inhibited the epithelial-mesenchymal transition (EMT) of
CRC cells. A negative correlation between miR-296 and S100A4 expression was observed in CRC tissues. Luciferase
reporter assays indicated that miR-296 inversely regulated the luciferase activity of 3’-UTR of S100A4. Herein, S100A4 was
found to be a downstream molecule of miR-296 in CRC. Furthermore, S100A4 mediated the anti-metastatic effects of
miR-296 on EMT, migration and invasion of CRC cells.
Conclusions: miR-296 functions as an anti-metastatic factor mainly by suppressing S100A4 in CRC. It potentially acts as a
prognostic predictor and a drug-target for CRC patients.
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Background
Colorectal cancer (CRC), which is the third most common
cancer worldwide, is the fourth most common cause of
cancer-related deaths [1]. Although remarkable progresses
have been made in the diagnosis and treatment of CRC,
the survival of CRC patients is still dismal [2]. Systemic
metastasis and postoperative recurrence are the main rea-
sons for the unsatisfactory prognosis of CRC patients [3].
However, the molecular mechanisms underlying the me-
tastasis and recurrence of CRC remain largely unknown.
Therefore, it is of great significance to understand the
molecular mechanisms for the metastasis and recurrence
of CRC.
microRNAs (miRNAs) inhibit the expression of target
genes by contributing to the degradation or transla-
tional inhibition of target mRNAs [4]. They have been
found to be actively involved in different cellular pro-
cesses [5, 6] including cell proliferation, apoptosis,
differentiation and movement. Emerging studies show
that abnormal expression and dysfunction of miRNAs
play important roles in the pathogenesis and tumorigen-
icity of human malignancies [7–9]. Otherwise, miRNAs
have been demonstrated to be hopeful diagnostic bio-
markers and drug-targets of CRC [10–12]. Investigating
the expression and biological function of miRNAs in CRC
will contribute to the discovery of new biomarkers and
drug-targets for CRC patients.
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Recently, miRNA-296 was found to play important
roles in various human cancers including lung cancer
[13, 14], glioblastoma [15], bladder cancer [16], and
laryngeal carcinoma [16]. Study of lung cancer showed
that miR-296 could inhibit the proliferation and enhanced
the apoptosis of lung cancer cells [13, 14]. And miR-296
played a suppressive role in glioblastoma by inhibiting
glioblastoma cell stemness [15]. However, miR-296 ex-
pression contributed to the resistance to radiotherapy and
tumor recurrence of laryngeal carcinoma [16], indicating
an oncogenic role of miR-296 in laryngeal carcinoma.
These indicate that miR-296 plays different roles in differ-
ent cancer types. Previous study has reported that
decrease in blood miR-296 predicts chemotherapy resist-
ance and poor clinical outcome in patients receiving
systemic chemotherapy for metastatic colon cancer [17].
In azoxymethane (AOM)-treated rat model, miR-296-5p
was downregulated in the uninvolved colonic mucosa
(tumor field) of AOM rats [18]. However, the expression
and biological role of miR-296 in CRC remain unknown.
Here, we confirmed that miR-296 was underexpressed in
CRC specimens and cells. The low level of miR-296 corre-
lated with adverse clinical features of CRC patients and
decreased survival rate. Our data showed that miR-296
inhibited the mobility and epithelial-mesenchymal transi-
tion (EMT) of cancer cells in CRC. Moreover, S100A4 was
identified as a downstream molecule of miR-296 and medi-
ated the biological functions of miR-296 in CRC.
Methods
Clinical tissues
Clinical specimens were obtained from 90 histologically
diagnosed CRC patients in the Chinese PLA General
Hospital. Patients who received immunotherapy, chemo-
therapy or radiotherapy before surgical treatment were
excluded. All specimens were stored in liquid nitrogen
or fixed with formalin for further investigation. The
demographic features and clinicopathologic date were
shown in Table 1.
Cell culture and transfection
Human colorectal cancer cell lines including HCT116,
Caco-2, HT29,SW620, and SW480, and human intestinal
epithelial cells (HIEC) were obtained from the Institute of
Biochemistry and Cell Biology, Chinese Academy of
Sciences (Shanghai, China). All cells were cultured in
DMEM (HyClone, Logan, UT, USA) along with fetal
bovine serum (10%) (FBS; HyClone), penicillin (100 U/ml;
Sigma, St-Louis, MO, USA), and streptomycin (100 μg/
ml; Sigma). Cell cultures were kept in a incubator con-
taining of 5% CO2 and humidified atmosphere at 37 °C.
miR-296 mimic, miR-296 inhibitor, S100A4 siRNA and
the corresponding control vectors were bought from Gen-
ecopoeia (Guangzhou, China) and were then transduced
into CRC cells with lippofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) following manufactures’ protocols.
Retroviral vector pMMP-S100A4 was constructed by
inserting the corresponding cDNA into pMMP. The ret-
roviruses were packaged and tranfected into CRC cells as
previously described [19].
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA from CRC cells was extracted by miRNeasy
Mini Kit (Qiagen, Hilden, Germany) and total RNA from
CRC tissues were extracted with Trizol reagent (Ambion,
Austin, TX, USA). miR-296 levels in these samples were
assayed using TaqMan MicroRNA assays based on the
manufacturer’s instructions (Applied Biosystems,
Carlsbad, CA). The primers for miR-296 and U6 were
obtained from Genecopoeia (Guangzhou, China). U6
was used as the control gene for the relative level of
miR-296.
Luciferase reporter assay
To investigate whether miR-296 could interact with the
3’-UTRs of S1004, wild type (wt) 3’-UTR of S100A4
predicted to interact with miR-296 or the mutant (mt)
S100A4 3’-UTR was amplified and cloned into plasmids.
Then, the wt 3’-UTR of S100A4 or mt 3’-UTR of
S100A4, and miR-296 mimic or miR-296 inhibitor were
co-transduced into CRC cells by lippofectamine 2000
(Invitrogen). 48 h after co-transfection, the cells were
lysed and assayed using Dual-Luciferase® Reporter Assay
Table 1 Clinicopathological findings and correlation with
miR-296 expression in CRC
Features n = 90 miR-296 expression P
Low High
Age (years) <65 59 30 (50.85%) 29 (49.15%) 0.824
≥65 31 15 (48.39%) 16 (51.61%)
Sex Male 48 26 (54.17%) 22 (45.83%) 0.398
Female 42 19 (45.24%) 23 (54.76%)
Tumor grade G1 + G2 67 35 (52.24%) 32 (47.76%) 0.468
G3 + G4 23 10 (43.48%) 13 (56.52%)
Size (cm) <5 30 17 (56.67%) 13 (43.33%) 0.371
≥5 50 28 (56.00%) 32 (44.00%)
Tumor invasion T1 + T2 22 5 (22.73%) 17 (77.27%) 0.003*
T3 + T4 68 40 (58.82%) 28 (41.18%)
Lymph node status <1 48 16 (33.33%) 32 (66.67%) 0.001*
≥1 42 29 (69.05%) 13 (30.95%)
Distant metastasis Absent 69 30 (43.48%) 39 (56.52%) 0.025*
Present 21 15 (71.43%) 6 (28.57%)
TNM stage I + II 43 16 (37.21%) 27 (62.79%) 0.020*
III + IV 47 29 (61.70%) 18 (38.30%)
CRC colorectal cancer, TNM tumor-node-metastasis. * Statistically significant
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Kit (Promega, Madison, WI, USA) based on the manu-
facturer’s protocols.
Wound healing assay
CRC cells transfected with corresponding vectors were
seeded in 6-well plates to form the single confluent cell
layer. The wound were made with 100 μl tips in the
confluent cell layer. 0 and 12 h after would scratching,
the width of wound was photographed with phase-
contrast microscope.
Transwell migration and invasion assay
The migratory and invasive ability of CRC cells were
evaluated with Transwell chambers (BD Biosciences,
Franklin Lakes, NJ, USA). 5–10 × 104 CRC cells that
were suspended in 100 μl medium without serum were
seeded into the upper chamber, and lower chamber was
full of 20% FBS to induce CRC cells migrating or invad-
ing through the membrane. Matrigel (1:6 dilution; BD
Biosciences) was added on the upper chamber for inva-
sion assay. 24 h later, cells with crystal violet (MedChem
Express, Shanghai, China) staining that migrated or in-
vaded across the Transwell membrane were counted
under optical microscope.
Western blot
Cell proteins were collected with RIPA lysis buffer
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
and 40ug protein were subjected to 4-20% SDS gel elec-
trophoresis (Sigma) and were then transferred to PVDF
membranes (Roche, Indianapolis, IN, USA). Then, 5%
milk blocked membranes were incubated with S100A4
(1:1000, Abcam, Cambridge, UK), E-cadherin (1:500,
Abcam) or Vimentin (1:1000, Abcam) antibody and sub-
sequently incubated with matched secondary antibodies
(Cell signaling, Danvers, MA, USA). Then, signals for
each protein expression were detected with the Bio-Rad
Gel imaging system (Bio-Rad, Hercules, CA, USA).
GAPDH (G8140, US Biological, Swampscott, MA, USA)
was used as a loading control.
Immunofluorescence (IF)
CRC cells were seeded on chamber slides and were fixed
with 4% paraformaldehyde for 10 min at room
temperature. Then, cells were incubated with antibodies
against E-cadherin (1:50, Abcam) or Vimentin (1:100,
Abcam) at 4 °C overnight. Then, the slides were incu-
bated with matched secondary antibodies (Invitrogen) at
room temperature for 1 h. The nuclear of CRC cells
were stained with DAPI (Sigma) at room temperature
for 10 min. Fluorescence confocal images were captured
using a LSM 5 Pa Laser Scanning Microscope(Zeiss
Germany, Oberkochen, Germany).
Immunohistochemistry (IHC)
Before IHC staining, CRC tissues were fixed with 10% for-
malin and embedded with paraffin. Then, the embedded
tissues were cut into 4 μm thick sections. IHC staining fol-
lowing the standard protocol was performed to evaluate
the expression level of S100A4, E-cadherin, and Vimentin
in CRC tissues.
Statistical analysis
All data were collected and showed as Mean ± SEM.
Statistical analyses including Pearson chi-squared test, a
two-tailed Student’s t test, Kaplan-Meier analysis, Log-
rand test, Cox regression analysis and Spearman’s correl-
ation analysis were performed with GraphPad Prism 5
software (GraphPad Software, Inc, San Diego, CA, USA)
were used in this study to perform statistical analysis.
P < 0.05 was considered to be statistically different.
Results
miR-296 expression is decreased in CRC
To examine the status of miR-296 in CRC, qRT-PCR
was performed on 90 CRC cases. Our data disclosed that
CRC tissues showed significant decreased expression
levels of miR-296 (P < 0.05, Fig. 1a). Next, we compared
the expression levels of miR-296 between CRC cells lines
and HIEC cells. Compared with HIEC cells, the levels of
miR-296 in all CRC cells (HCT116, Caco2, HT29,
SW620 and SW480) were significantly reduced (P < 0.05,
Fig. 1b). These data indicate miR-296 probably plays a
suppressive role in CRC.
Underexpression of miR-296 correlates with adverse
clinical parameters and poor prognosis of CRC patients
To clarify the clinical value of miR-296 in CRC, all
patients were grouped into miR-296 low and high
expression groups according to the median expression
of miR-296. As shown in Table 1, CRC patients with
low expression of miR-296 had high tumor invasion stage
(P = 0.003), increased lymph node metastasis (P = 0.001)
and distant metastasis (P = 0.025), and advanced tumor-
node-metastasis (TNM) stage (P = 0.020). Furthermore,
survival analyses indicated that patients with low expres-
sion of miR-296 showed significantly reduced 5-year over-
all and recurrence-free survival (P = 0.046 and P = 0.006,
respectively, Fig. 1c and d). The Cox-regression analysis
showed that lymph node status, distant metastasis, TNM
stage and miR-296 expression were independent factors
for the overall survival and disease free survival of CRC
patients (P < 0.05, respectively, Table 2). We suggest that
miR-296 is a possible prognostic biomarker for CRC
patients.
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miR-296 inhibits the mobility of CRC cells
Since increased cancer cell mobility is a important rea-
son for the metastasis and recurrence of human cancer
[20], we explored whether miR-296 could modulate the
migration and invasion of CRC cells. Transfection of
miR-296 mimic obviously up-regulated the level of miR-
296 in HT29 cells (P < 0.05, Fig. 2a). The wound healing
assays showed that miR-296 overexpression notably
reduced cell migration in HT29 cells (Fig. 2b). And
Transwell assays explored that ectopic expression of
miR-296 significantly reduced the numbers of migrated
and invaded HT29 cells (P < 0.05, respectively, Fig. 2c).
In turn, miR-296 inhibitor significantly decreased the
level of miR-296 in SW480 cells (P < 0.05, Fig. 3a). Sub-
sequently, miR-296 silencing notably facilitated SW480
cell migration and invasion (P < 0.05, respectively, Fig. 3b
and c). Thus, miR-296 exerts a anti-metastatic role in
CRC cells.
miR-296 regulates S100A4 expression and epithelial-
mesenchymal transition in CRC cells
To disclose the underlying molecular mechanisms in-
volved in the role of miR-296 in CRC cells, TargetScan-
Human 7.1 (http://www.targetscan.org) was used for
discovery of the target molecule of miR-296. EMT has
been confirmed to be a critical mechanism for cancer
metastasis [21, 22]. S100A4, a marker of EMT pheno-
type [23] and also a critical regulator of cancer growth
and metastasis [24, 25], was recognized as a potential
target molecule of miR-296, because the complementary
sequence of miR-296 was identified in the 3’-UTR of
S100A4 mRNA by TargetScan analysis. Further experi-
ments were performed to confirm the above hypothesis.
Western blot showed that miR-296 overexpression in
HT29 cells significantly increased the level of epithelial
marker E-cadherin, and decreased the expression of
mesenchymal markers including Vimentin and S100A4
Fig. 1 The status and prognostic value of miR-296 expression in CRC. a The expression differences of miR-296 between CRC tissues and normal
tumor-adjacent tissues. n = 90. b The expression differences of miR-296 between 5 different CRC cells lines (HCT116, Caco2, HT29, SW620, SW480)
and HIEC cells. *P < 0.05 versus HIEC cells. c and d Compared with those of high miR-296 level (n = 45), miR-296 low-expressing patients (n = 45)
had significantly reduced overall survival and recurrence-free survival
Table 2 Multivariate analysis for OS and DFS of 90 CRC patients
Variables OS DFS
HR 95% CI P HR 95% CI P
Tumor invasion (T1/T2 vs T3/T4) 0.82 (0.33-2.00) 0.658 0.77 (0.31-1.90) 0.567
Lymph node status (<1 vs ≥1) 2.35 (1.25-4.41) 0.008* 2.43 (1.30-4.59) 0.006*
Distant metastasis (Absent vs Present) 7.89 (4.58-13.61) <0.001* 9.41 (5.49-16.16) <0.001*
TNM stage (I/II vs III/IV) 1.61 (1.01-2.59) 0.049* 1.77 (1.10-2.86) 0.019*
miR-296 expression (Low vs High) 0.44 (0.22-0.86) 0.016* 0.43 (0.27-1.02) 0.038*
OS overall survival, DFS disease-free survival, CRC colorectal cancer, TNM tumor-node-metastasis. * Statistically significant
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(Fig. 4a). And the immunostaining accordingly showed
that miR-296 overexpression evidently increased E-
cadherin expression and decreased Vimentin express-
sion (Fig. 4b). On the other hand, miR-296 silencing
in SW-480 cells prominently decreased E-cadherin
expression, and increased Vimentin and S100A4
expression (Fig. 4c). And immunofluorescence data
showed that E-cadherin expression was decreased
while Vimentin expression was increased after miR-
296 knockdown (Fig. 4d).
Fig. 2 miR-296 overexpression inhibits the mobility of HT29 cells. a HT29 cells that were transduced with negative control mimics (miR-control)
or miR-296 mimics were confirmed by qRT-PCR. n = 3, *P < 0.05. b Wound healing assays indicated that miR-296 overexpression reverses the
migration of HT29 cells. c Transwell assays confirmed that miR-296 overexpression inhibited HT29 cell migration and invasion. n = 3, *P < 0.05
Fig. 3 miR-296 knockdown facilitates the metastasis of SW480 cells. a SW480 cells that were transduced with negative control inhibitors (NC) or
miR-296 inhibitors (anti-miR-296) were confirmed by qRT-PCR. n = 3, *P < 0.05. b miR-296 knockdown notably facilitated the migration of SW480
cells. c miR-296 knockdown prominently promoted SW480 cell migration and invasion. n = 3, *P < 0.05
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To further confirm that miR-296 could modulate
EMT phenotype of CRC, IHC was performed in CRC
tissues for S100A4, E-cadherin and Vimentin. miR-296
low expressing tumors showed strong staining of
S100A4 (Fig. 5a) and Vimentin (Fig. 5e), and weak stain-
ing of E-cadherin (Fig. 5c). However, miR-296 high
expressing tumors showed weak staining of S100A4
(Fig. 5b) and Vimentin (Fig. 5f ), and strong staining of
E-cadherin (Fig. 5f ). Spearman’s correlation analysis
indicated that miR-296 was strongly correlated with
S100A4 (r = −0.784, P = 0.002), E-cadherin (r = 0.531,
P = 0.013) and Vimentin (r = −0.638, P = 0.028) expres-
sion in CRC specimens. These data indicate that miR-296
can inhibit the metastasis of CRC cell by modulating
EMT phenotype.
miR-296 post-transcriptionally regulates S100A4
expression
We further explored whether S100A4 was a downstream
target molecule of miR-296. As shown in Fig. 6a, the
putative bind sites for miR-296 was presented in the 3’-
UTR of S100A4. Then, we performed luciferase reporter
assays to investigate whether miR-296 could bind to the
putative binding sites in the 3’-UTR of S100A4. Overex-
pression of miR-296 decreased the luciferase activity of
wt 3’-UTR of S100A4 (P < 0.05, Fig. 6b) while inhibition
of miR-296 increased the luciferase activity of wt 3’-UTR
of S100A4 (P < 0.05, Fig. 6b). And alteration of miR-296
did not have any influence on the luciferase activity of
mt 3’-UTR of S100A4 (Fig. 6b). Therefore, these data in-
dicate miR-296 can regulate the expression of S100A4
by directly interacting with its 3’-UTR in CRC.
S100A4 mediates the anti-metastatic effects of miR-296
on CRC cells
Since we confirmed S100A4 was a target molecule of
miR-296, S100A4 retroviruses were employed to disclose
whether S100A4 restoration could abolish the anti-
metastatic role of miR-296 in CRC cells. As shown in
Fig. 7a, S100A4 retroviruses infection significantly
Fig. 4 miR-296 inhibits the epithelial-mesenchymal transition of CRC cells. a Western blot showed overexpression of miR-296 decreased
S100A4 and Vimentin expression, and increased E-cadherin expression in HT29 cells. b Immunofluorescence showed miR-296 overexpression increased
E-cadherin expression and decreased Vimentin expression in HT29 cells. cWestern blot showed knockdown of miR-296 increased S100A4 and Vimentin
expression, and decreased E-cadherin expression in SW480 cells. d Immunofluorescence showed knockdown of miR-296 decreased E-cadherin expression
and increased Vimentin expression in SW480 cells
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increased the levels of S100A4 and Vimentin while re-
duced E-cadherin expression in miR-296 overexpressing
HT29 cells. Consequently, restoration of S100A4 pro-
moted the metastatic behavior of miR-296 overexpress-
ing HT29 cells with enhanced cell migration and
invasion (P < 0.05, respectively, Fig. 7b and c). In turn,
S100A4 knockdown abolished the effects of miR-296
silencing on EMT, migration and invasion of SW480
cells (P < 0.05, respectively, Fig. 8a-c). Since miRNAs
usually have multiple targets, further experiments were
performed to check whether the cell mobility will be fur-
ther inhibited or not after over-expression of miR-296 in
S100A4 knockdown cells. Our data indicated that miR-
296 overexpression slightly reduced the number of
migrated and invaded S100A4 knockdown HT29 cells
without statistical significance (Additional file 1: Figure
S1), suggesting that S100A4 was the major functional
target of miR-296. Taken together, these experiments
suggest that S100A4 is not only a downstream target but
also a mediator of miR-296 in CRC.
Discussion
Emerging evidences have confirmed that miRNAs are
actively involved in the pathogenic process of CRC [26].
And miRNAs have been found to be critical regulators
of the metastasis and EMT of CRC cells [27]. According
to the important function of miRNAs in CRC, miRNAs
have been considered as potential diagnostic biomarkers
and drug-targets of CRC [28]. Decreased expression of
miR-296 has been found in metastatic colon cancer
patients’ blood and AOM-induced CRC rat model [17, 18].
In this study, miR-296 was found to be significantly
downregulated in CRC tissues and cells. And decreased
expression of miR-296 in CRC tissues conferred malignant
Fig. 5 The expression of S100A4, E-cadherin, and Vimentin in CRC tissues. In representative immunohistochemical staining, miR-296 low expressing
tumors showed strong staining of (a) S100A4 and (e) Vimentin, and weak staining of (c) E-cadherin. However, miR-296 high expressing tumors showed
weak staining of (b) S100A4 and (f) Vimentin, and strong staining of (d) E-cadherin. Scale bar: 50 μm
Fig. 6 miR-296 binds to the complementary sequence in S100A4
3’-UTR. a The binding sites for miR-296 in wild type (wt) and mutant
(mt) 3’-UTR of S100A4. b Overexpression of miR-296 decreased while
inhibition of miR-296 increased the luciferase activity of wt 3’-UTR of
S100A4. Alteration of miR-296 had no effect on the luciferase activity of
mt 3’-UTR of S100A4. n = 3, *P < 0.05
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Fig. 7 S100A4 restoration reverses the effects of miR-296. a miR-296 overexpressing HT29 cells that were infected with empty vector (EV) or
S100A4 retroviruses were confirmed by western blotting for S100A4, E-cadherin and Vimentin. b S100A4 restoration significantly promoted the
migration of miR-296 overexpressing HT29 cells. c S100A4 restoration evidently facilitated cell migration and invasion in miR-296 overexpressing
HT29 cells. n = 3, *P < 0.05
Fig. 8 S100A4 knockdown abrogates the effects of miR-296 inhibition on EMT, migration and invasion of CRC cells. a miR-296 silenced SW480
cells that were transfected with S100A4 siRNA and scrambled siRNA (scr siRNA) were subjected to western blot. S100A4 siRNA significantly decreased
S100A4 in miR-296 silenced SW480 cells, and led to increased E-cadherin expression and decreased Vimentin expression. b S100A4 knockdown significantly
inhibited the migration of miR-296 silenced SW480 cells. c S100A4 knockdown significantly inhibited the migration and invasion of miR-296 silenced
SW480 cells. n = 3, *P< 0.05
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clinical features of CRC patients including high tumor in-
vasion stage, lymph node metastasis, distant metastasis,
and advanced TNM stage. More importantly, decreased
miR-296 was correlated with reduced overall survival and
disease-free survival of CRC patients, and was found to be
an independent factor for the prognosis of CRC patients.
Therefore, miR-296 plays a tumor suppressive role in
CRC and could potentially serve as a promising biological
tag for the prognosis of patients.
Systemic metastasis is the important reason for the
unsatisfactory prognosis of CRC patients [2]. Increased
migratory and invasive ability of CRC cells underlies the
systemic metastasis of CRC. Therefore, it is of great
importance to elucidate the molecular mechanisms for
the metastasis of CRC cells. In this study, we found that
miR-296 could inhibit migration and invasion of CRC
cells in vitro. These data confirm that miR-296 exerts a
tumor suppressive role in CRC by inhibiting metastatic
behaviors of CRC cells. Moreover, previous studies have
showed that EMT is a hallmark of human cancer and is
a critical mechanism for cancer metastasis. Therefore,
we further investigated whether miR-296 could influence
the metastasis of CRC cells by regulating EMT pheno-
type. Our data showed that overexpression of miR-296
could inhibit EMT of CRC cells while inhibition of miR-
296 promoted EMT of CRC cells. Immunohistochemical
staining of CRC specimens further confirmed the correl-
ation between the expression of miR-296 and EMT
markers. Taken together, these data demonstrate that
miR-296 can suppress the metastasis of CRC cells by inhi-
biting EMT.
S100A4 is a well-known regulator of the growth and
metastasis of human cancers [23, 25]. In CRC, S100A4
was found to be aberrantly up-regulated and correlated
with the metastatic phenotype of CRC cells [24]. In this
study, we found that miR-296 could inhibit the expres-
sion of S100A4 in CRC cells. And the expression of
S100A4 in CRC tissues was negatively correlated with
the expression level of miR-296. Moreover, we found
that miR-296 could directly interact with the 3’-UTR of
S100A4 using luciferase reporter assay. These data indi-
cate that S100A4 is a direct downstream target of miR-
296. Furthermore, we found that restoration of S100A4
reversed the anti-metastatic effects of miR-296 overex-
pression and S100A4 knockdown abrogate the effects of
miR-296 inhibition on EMT and metastasis of CRC cells.
Moreover, we disclosed that S100A4 was the major func-
tional target of miR-296 in CRC. These suggest that
S100A4 is not only a downstream target but also a medi-
ator of miR-296 in CRC.
All together, our study demonstrates that miR-296
expression is significantly decreased in CRC. The low
level of miR-296 correlates with adverse clinical parame-
ters of CRC patients and shortened survival. And miR-
296 inhibits the EMT and metastasis of CRC cells. Fur-
thermore, S100A4 is a downstream target of miR-296 in
CRC. Altogether, miR-296 exerts its inhibitory effects on
CRC metastasis mainly by targeting S100A4.
Conclusions
Dysfunction of miRNAs has been implicated in the initi-
ation and progression of human cancers. miR-296 was
previously found to be a cancer-related miRNAs. Recent
study reported that decreased in blood miR-296 pre-
dicted chemotherapy resistance and poor clinical out-
come in patients receiving systemic chemotherapy for
metastatic colon cancer. Yet, the clinical value and bio-
logical function of miR-296 remain rarely known in
CRC. Here, we presented that miR-296 level in CRC
tissues was notably reduced compared to matched non-
cancerous specimens. Its decreased level was evidently
correlated with adverse clinical parameters including
tumor invasion, lymph node metastasis, distant metasta-
sis and advanced TNM stage, and poor prognosis of
CRC patients. Accordingly, the levels of miR-296 were
obviously down-regulated in CRC cells compared to
HIEC cells. Ectopic expression of miR-296 in HT29 cells
prominently inhibits the migration and invasion of
tumor cells, while miR-296 knockdown increased these
behaviors of SW480 cells. Mechanically, miR-296
exerted an anti-metastatic function by suppressing EMT
and S100A4 abundance in CRC cells. Herein, S100A4
was found to be a downstream molecule of miR-296 in
CRC. A significant correlation between miR-296 and
S100A4, E-cadherin and Vimentin was confirmed in
CRC specimens. Furthermore, restoration of S100A4
expression could abrogate the anti-metastatic effects of
miR-296 on HT29 cells with enhanced cell migration
and invasion. S100A4 knockdown inhibited the migra-
tion and invasion of miR-296 underexpressing SW480
cells. Altogether, miR-296 potentially act as a prognostic
predictor and a drug-target for CRC patients.
Additional file
Additional file 1: Figure S1. miR-296 overexpression doesn’t notably
reduced cell migration and invasion in S100A4 knockdown HT29 cells.
S100A4 knockdown HT29 cells that were transfected with negative
control mimics (miR-control) and miR-296 mimics, respectively, were
subjected to Transwell assays for cell migration and invasion. Quantitative
data indicated that miR-296 overexpression slightly reduced cell migration
and invasion in S100A4 knockdown HT29 cells. n = 3 repeats with similar
results. (TIF 674 kb)
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